
Alexion drops kidney disease program for drug that was part of $930M Achillion buyout last year
The company said in its 2Q earnings that it would halt development of ALXN2040 for C3 glomerulopathy, or C3G, citing the drug’s lack of potency. […]
The company said in its 2Q earnings that it would halt development of ALXN2040 for C3 glomerulopathy, or C3G, citing the drug’s lack of potency. […]
Copyright © 2022 | WordPress Theme by MH Themes